Journal
CELL HOST & MICROBE
Volume 4, Issue 5, Pages 470-483Publisher
CELL PRESS
DOI: 10.1016/j.chom.2008.09.012
Keywords
-
Categories
Funding
- Medical Research Council (MRC)
- Cancer Research UK
- Biotechnology and Biological Sciences Research Council (BBSRC)
- MRC [G9825083, G0800168] Funding Source: UKRI
- Medical Research Council [G9825083, G0800168] Funding Source: researchfish
Ask authors/readers for more resources
The involvement of Toll-like receptor 4 (TLR4) in immunity against human herpesviruses has not been previously demonstrated. We show that infection of endothelial cells with Kaposi sarcoma herpesvirus (KSHV), a human oncogenic virus, leads to rapid suppression of TLR4 expression. This is a mechanism of immune escape as TLR4 mediates innate immunity against KSHV. In vitro, cells lacking TLR4 are more susceptible to KSHV infection, whereas activation of TLR4 protects cells from infection. In vivo, HIV-1-infected individuals carrying a mutant TLR4 allele appear more likely to have multicentric Castleman's disease, a lymphoproliferation associated with enhanced KSHV replication. ERK activation by KSHV structural proteins and the KSHV-encoded vGPCR plays a key role in the TLR4 downregulation, whereas the KSHV vIRF1 also contributes to this effect. Our findings reveal a role for TLR4 in innate immunity against herpesviruses and suggest the potential use of TLR4 agonists for the treatment of KSHV-related neoplasms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available